Numinus and Cedar Clinical Research Join Beckley Psytech’s Phase 2b Psychedelic Trial for Depression

Numinus Wellness Inc. recognized for approach to mental health care, has announced a significant milestone in psychedelic-assisted therapies. Its research arm, Cedar Clinical Research (CCR), has been selected as a pivotal site for a groundbreaking Phase 2b clinical trial by Beckley Psytech, focusing on Treatment Resistant Depression (TRD).

This study is designed to assess the efficacy and safety of Beckley Psytech’s unique intranasal formulation of synthetic 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), known as BPL-003. The trial follows the U.S. FDA’s approval for the Phase 2b study of this short-acting psychedelic compound, a first in its category. CCR’s involvement in this trial reinforces its position as a leader in psychedelic clinical research and aligns with its commitment to exploring innovative mental health solutions.

Dr. Paul Thielking, Chief Science Officer at Numinus, expressed excitement about supporting Beckley Psytech in this clinical endeavor. He emphasized that such collaborations not only showcase CCR’s dedication to mental health research but also highlight its world-class infrastructure and expertise, positioning it as a top clinical research hub.

Numinus and CCR’s partnership with Beckley Psytech is a testament to their joint mission to pioneer in psychedelic-assisted therapies. This collaboration is expected to provide transformative insights for the medical community, furthering the understanding and potential of psychedelic treatments in mental health care.

Numinus and CCR continue to lead in the advancement of psychedelic-assisted therapies, emphasizing their deep commitment to research that fosters comprehensive healing and mental wellness. For more information about this study, interested parties are directed to Beckley Psytech’s website.